Actively Recruiting
Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
Led by Mackay Memorial Hospital · Updated on 2025-05-09
200
Participants Needed
1
Research Sites
237 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.
CONDITIONS
Official Title
Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 40 to 90 years
- Diagnosed with detrusor overactivity confirmed by urodynamic testing
- Refractory to monotherapy with anti-muscarinic drugs
You will not qualify if you...
- Postvoid urine retention before treatment
- Medical illnesses or contraindications for solifenacin or mirabegron, such as narrow-angle glaucoma and hypertension
- History of cerebrovascular disease, thromboembolic disorders, gallbladder disease, breast carcinoma, estrogen-dependent neoplasm, or unexplained genital bleeding
- Hormone replacement therapy use within the past 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mackay Memorial Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
H
Hui-Hsuan Lau, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here